Citable numbers on GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide) — market size, prescription volume, user demographics, clinical outcomes, pricing, insurance, side effects, and regulatory actions. Every stat is sourced. Use the anchor links to cite specific numbers.
1. Market size and growth
GLP-1 receptor agonists are the fastest-growing pharmaceutical class in modern history. Combined sales by Novo Nordisk and Eli Lilly are reshaping global pharma economics.
Combined Novo Nordisk + Eli Lilly GLP-1 class revenue, 2018-2030 (USD billions)
Sources: Novo Nordisk + Eli Lilly annual reports (2018-2024). 2025-2030 projections from industry consensus (Goldman Sachs, J.P. Morgan, Grand View Research). Verified 2026-04-27.
Global GLP-1 receptor agonist class revenue (2024)
Combined disclosed revenue across Novo Nordisk (Ozempic + Wegovy + Saxenda + Rybelsus) and Eli Lilly (Mounjaro + Zepbound + Trulicity), based on each company’s annual report disclosures. The class crossed $50B for the first time in 2024.
Sources: Novo Nordisk Annual Report 2024; Eli Lilly Annual Report 2024. Verified 2026-04-27.
Wegovy + Ozempic combined annual revenue (Novo Nordisk, 2024)
Wegovy alone generated approximately $8-9B in 2024; Ozempic generated approximately $14-15B. Together, they account for the majority of Novo Nordisk’s diabetes & obesity care revenue.
Source: Novo Nordisk 2024 Annual Report. Verified 2026-04-27.
Mounjaro + Zepbound combined annual revenue (Eli Lilly, 2024)
Eli Lilly’s tirzepatide franchise grew rapidly after Zepbound’s November 2023 FDA approval for weight management. Both drugs combined exceeded $12B in 2024.
Source: Eli Lilly 2024 Annual Report. Verified 2026-04-27.
Projected GLP-1 class market size by 2030 (industry consensus)
Multiple investment-bank and industry-research forecasts (Goldman Sachs, J.P. Morgan, Grand View Research, Morgan Stanley) converge around $130-150B by 2030, driven by obesity expansion, oral formulations, and CV-outcomes label expansions.
Source: industry consensus forecasts. As of 2026.
Combined Novo Nordisk + Eli Lilly share of global GLP-1 market (2024)
Other manufacturers (AstraZeneca with Byetta/Bydureon; some smaller players) hold roughly 30%. Novo and Lilly’s duopoly is reinforced by patent protection on semaglutide (through 2031 in the US) and tirzepatide.
Source: aggregated from manufacturer disclosures. Verified 2026-04-27.
2. Prescription volume
US GLP-1 prescription fills doubled between 2022 and 2024 and continued growing through 2025-2026.
Share of US adults who report having ever used a GLP-1 (2024 KFF survey)
A May 2024 KFF Health Tracking Poll found about 1 in 8 US adults (12%) reported they had ever taken a GLP-1 drug. About 6% reported current use. Numbers have continued to climb.
Source: KFF Health Tracking Poll, May 2024. Verified 2026-04-27.
US weekly GLP-1 prescription fills (2024 estimate)
IQVIA pharmacy fill data showed weekly GLP-1 prescriptions exceeded 9 million in 2024, up from approximately 4 million in 2022. The category includes Ozempic (largest share), Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, and Victoza.
Source: IQVIA pharmacy claims data; reported in Reuters and Endpoints News coverage. Verified 2026-04-27.
Approximate growth in US GLP-1 prescriptions, 2022 → 2024
Total US GLP-1 prescription volume roughly doubled in 24 months as Wegovy and Zepbound entered the weight-loss market and Ozempic / Mounjaro saw off-label weight-loss prescribing.
Source: IQVIA pharmacy claims data. Verified 2026-04-27.
GLP-1 prescription share that is for off-label / weight-related use (estimate)
Studies of pharmacy claims data suggest a sizeable minority of Ozempic and Mounjaro prescriptions are written for weight management even though the drugs are FDA-approved only for type 2 diabetes (the weight-loss indications are Wegovy and Zepbound respectively).
Source: JAMA Health Forum analysis; aggregated pharmacy claims studies. Verified 2026-04-27.
3. User demographics
Who is actually taking GLP-1s? Demographics from KFF surveys, manufacturer disclosures, and CDC data.
Approximate female-to-male ratio of GLP-1 weight-loss users (2024)
Pharmacy claims and survey data consistently show women fill roughly twice as many weight-loss GLP-1 prescriptions (Wegovy, Zepbound, Saxenda) as men. The diabetes-indicated drugs (Ozempic, Mounjaro, Trulicity) skew closer to 50/50.
Source: pharmacy claims analyses, manufacturer commercial disclosures. Verified 2026-04-27.
US adults with obesity (BMI ≥30) who would be eligible for Wegovy or Zepbound (2024 estimate)
Per CDC NHANES data, approximately 42% of US adults have obesity (BMI ≥30); when adding adults with BMI 27-29.9 plus a weight-related comorbidity (the broader Wegovy/Zepbound label criterion), the eligible population approaches half of US adults.
Source: CDC NHANES Adult Obesity Data; FDA prescribing information (Wegovy / Zepbound). Verified 2026-04-27.
US adults age 50-64 who report having ever used a GLP-1 for weight loss (KFF survey subset)
GLP-1 use is highest among middle-aged adults. The 50-64 age group reports the highest weight-loss-indication use, reflecting both higher BMI prevalence and greater willingness to consider pharmacologic interventions.
Source: KFF Health Tracking Poll. Verified 2026-04-27.
4. Clinical outcomes (from RCTs)
Efficacy data from the registration trials, expressed as percent body-weight loss versus placebo at the trial endpoint.
Mean body-weight reduction in pivotal weight-loss RCTs (% at trial endpoint)
Sources: STEP 1 (PMID 33567185), SURMOUNT-1 (PMID 35658024), SCALE, COR-I, orlistat 1-year meta-analysis. Each bar is mean weight loss at trial endpoint vs placebo + lifestyle. Verified 2026-04-27.
Mean body-weight reduction with semaglutide 2.4 mg vs 2.4% placebo at 68 weeks (STEP 1)
Semaglutide 2.4 mg/week (Wegovy) reduced body weight by a mean of 14.9% vs 2.4% on placebo plus lifestyle intervention at 68 weeks. Trial enrolled 1,961 adults with BMI ≥30 (or ≥27 with comorbidity). Approximately 50% of treated participants achieved ≥15% weight loss.
Source: Wilding et al., N Engl J Med 2021 (STEP 1); PMID 33567185. Verified 2026-04-27.
Mean body-weight reduction with tirzepatide 15 mg vs 3.1% placebo at 72 weeks (SURMOUNT-1)
Tirzepatide 15 mg/week (Zepbound) reduced body weight by a mean of 22.5% vs 3.1% on placebo at 72 weeks. Trial enrolled 2,539 adults with BMI ≥30 (or ≥27 with comorbidity). Approximately 36% of treated participants achieved ≥25% weight loss.
Source: Jastreboff et al., N Engl J Med 2022 (SURMOUNT-1); PMID 35658024. Verified 2026-04-27.
Semaglutide 2.4 mg vs liraglutide 3.0 mg head-to-head (STEP 8, 68 weeks)
Direct head-to-head: semaglutide 2.4 mg/week reduced body weight by 15.8% vs 6.4% with liraglutide 3.0 mg/day at 68 weeks. The first published head-to-head comparison of two FDA-approved weight-loss GLP-1s.
Source: Rubino et al., JAMA 2022 (STEP 8); PMID 35029554. Verified 2026-04-27.
Reduction in major adverse cardiovascular events with semaglutide 2.4 mg in non-diabetic adults with obesity + CVD (SELECT trial)
Semaglutide 2.4 mg reduced 3-point MACE (CV death, nonfatal MI, nonfatal stroke) by 20% vs placebo over a median 39.8 months. Trial enrolled 17,604 adults age ≥45 with BMI ≥27 and established CVD but without diabetes. Led to FDA’s March 2024 cardiovascular indication for Wegovy.
Source: Lincoff et al., N Engl J Med 2023 (SELECT); PMID 37952131. Verified 2026-04-27.
Body-weight regain after stopping tirzepatide (SURMOUNT-4 withdrawal)
Participants who switched from tirzepatide to placebo after the lead-in regained an average of 14% body weight by week 88, while those who continued tirzepatide maintained or extended their loss. Demonstrates that GLP-1 weight loss is largely treatment-dependent, not “curative.”
Source: Aronne et al., JAMA 2023 (SURMOUNT-4); PMID 38078870. Verified 2026-04-27.
Weight regain after stopping GLP-1 therapy (% body-weight change vs baseline)
Sources: STEP 1 + STEP 1 extension (Wilding 2021/2022); SURMOUNT-4 withdrawal phase (Aronne 2023). Continued-treatment line shows steady-state plateau; stopped line shows ~11.6 percentage-point regain in 12 months post-discontinuation.
Body-weight regain in the year after stopping semaglutide (STEP 1 extension)
In the STEP 1 trial extension, participants who stopped semaglutide and lifestyle intervention regained 11.6 percentage points of body weight, ending only 5.6% net below baseline at week 120.
Source: Wilding et al., Diabetes Obes Metab 2022; PMID 35441470. Verified 2026-04-27.
5. Pricing and out-of-pocket
List prices and savings-card out-of-pocket realities for the leading GLP-1s, US.
Wegovy list price per month (US, 2025)
Manufacturer list price (wholesale acquisition cost). Cash-paying patients without insurance see this on a pharmacy receipt absent any savings program.
Source: Wegovy.com; Novo Nordisk disclosed pricing. Verified 2026.
Zepbound list price per month (US, 2025; pen formulation)
List price for autoinjector pens. Lilly’s LillyDirect direct-to-consumer vial program offers Zepbound at $349-$599 per month (depending on dose) for cash-paying patients.
Source: Zepbound.com; LillyDirect. Verified 2026.
Ozempic list price per month (US, 2025)
Manufacturer list price. Most patients with commercial insurance plus a savings card pay $25/month, but uninsured patients face the full list price unless qualifying for the Ozempic Savings Card cash program.
Source: Ozempic.com; Novo Nordisk disclosed pricing. Verified 2026.
Typical out-of-pocket with commercial insurance + manufacturer savings card
Wegovy, Ozempic, Mounjaro, and Zepbound all offer savings cards that reduce out-of-pocket to approximately $25/month for the first 12 months for commercially-insured patients with on-formulary coverage. Government-insured patients (Medicare, Medicaid) are ineligible.
Source: manufacturer savings card terms (Wegovy WeGoTogether, Mounjaro Savings Card, Zepbound Savings Card). Verified 2026.
LillyDirect Zepbound vial cash price per month, by dose
Eli Lilly’s direct-to-consumer Zepbound vial program (launched 2024) offers cash-paying patients $349/mo for 2.5 mg, $499/mo for 5 mg, and $599/mo for 7.5+, 10, 12.5, 15 mg doses. Vials require self-reconstitution; pens are not available through this channel.
Source: LillyDirect.com. Verified 2026.
6. Insurance and coverage
Coverage for GLP-1s differs sharply between commercial, Medicare, and Medicaid — and between weight-loss vs T2D indications.
Medicare Part D coverage for weight-loss-indication GLP-1s (Wegovy, Saxenda, Zepbound)
A federal statute (the Medicare Modernization Act of 2003) explicitly excludes drugs prescribed for weight loss from Part D coverage. Wegovy, Saxenda, and Zepbound are therefore not covered for their weight-loss indications under any standard Medicare Part D plan. Some Medicare Advantage plans offer supplemental coverage.
Source: 42 U.S.C. § 1395w-102(e)(2)(A); CMS Medicare Part D regulations. Verified 2026.
Medicare Part D coverage for T2D-indicated GLP-1s
Ozempic, Mounjaro, Trulicity, Victoza, Bydureon, and Byetta are covered by Part D for type 2 diabetes when meeting prior-authorization criteria. The IRA caps annual out-of-pocket Part D drug spending at $2,000 starting 2025.
Source: CMS Part D formulary regulations; IRA implementation. Verified 2026.
Year Ozempic’s IRA-negotiated price takes effect
Ozempic was selected by CMS in August 2024 as one of 15 drugs in the second IRA Medicare drug-price negotiation tranche. The negotiated price (“Maximum Fair Price”) goes into effect January 1, 2027.
Source: CMS Medicare Drug Price Negotiation Program. Verified 2026-04-27.
US states whose Medicaid covers Wegovy or Zepbound for obesity (KFF estimate)
Approximately 13-15 state Medicaid programs covered weight-loss GLP-1s for adult obesity as of 2024-2025, with variation in BMI requirements and prior-authorization criteria. The figure has grown from ~7 states in 2023.
Source: KFF Medicaid GLP-1 Coverage Issue Brief. Verified 2026-04-27.
7. Side effect frequencies
Adverse event rates from the registration trials, with the percentage incidence on the active drug. Most are dose-related and ameliorate with slow titration.
Nausea incidence on semaglutide 2.4 mg (Wegovy STEP trials)
Approximately 44% of participants on semaglutide 2.4 mg experienced nausea at some point during titration, vs ~16% on placebo. Most cases were mild-to-moderate and self-resolving within weeks.
Source: Wegovy FDA Prescribing Information; STEP 1-4 pooled data. Verified 2026.
Nausea incidence on tirzepatide 15 mg (Zepbound SURMOUNT trials)
Approximately 29% of participants on tirzepatide 15 mg experienced nausea, generally lower than semaglutide 2.4 mg. Tirzepatide’s GIP component is hypothesized to attenuate the GI side-effect profile.
Source: Zepbound FDA Prescribing Information; SURMOUNT-1 trial. Verified 2026.
Acute pancreatitis incidence on GLP-1 receptor agonists (across class)
Pooled trial data show acute pancreatitis occurs in less than 1% of GLP-1 users. The signal is monitored by FDA but causal association at the population level remains debated; meta-analyses have produced mixed results.
Source: FDA prescribing information for GLP-1 class; Storgaard et al. meta-analyses. Verified 2026.
Medullary thyroid carcinoma (MTC) risk warning on all GLP-1s
All FDA-approved GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors based on rodent studies. Human relevance is unclear; contraindicated in patients with personal or family history of MTC or MEN-2 syndrome.
Source: FDA prescribing information for Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Trulicity, Victoza. Verified 2026.
Trial discontinuation rate due to adverse events on semaglutide 2.4 mg (STEP 1)
In STEP 1, about 7% of participants on semaglutide 2.4 mg discontinued due to adverse events, vs about 3.1% on placebo. Real-world discontinuation rates in commercial settings have been reported considerably higher (often 50%+ at 12 months) due to cost, access, and tolerability.
Source: Wilding et al., STEP 1, NEJM 2021; real-world rates from BMJ 2024 commercial-claims analysis. Verified 2026-04-27.
8. Regulatory and enforcement
Key FDA actions, drug shortage history, and compounding enforcement events shaping GLP-1 access.
Date FDA formally declared the semaglutide shortage resolved
FDA’s February 21, 2025 announcement formally ended the semaglutide drug shortage, removing the legal basis under FD&C Act § 503A and § 503B for compounding pharmacies to mass-produce semaglutide.
Source: FDA Clarifies Policies for Compounders as Shortages End. Verified 2026-04-27.
Date FDA formally declared the tirzepatide shortage resolved
FDA declared tirzepatide’s shortage resolved on October 2, 2024. After litigation by compounding industry groups, the FDA reaffirmed and finalized this on December 19, 2024.
Source: FDA Drug Shortages and Compounding GLP-1 Statement. Verified 2026-04-27.
503A compounding pharmacy enforcement deadline (semaglutide)
FDA enforcement discretion ended for 503A compounding pharmacies producing semaglutide on April 28, 2025. After this date, 503A pharmacies must stop mass-compounding semaglutide; only individualized patient-specific compounding remains legal.
Source: FDA Compounding Policy Statement, Feb 2025. Verified 2026-04-27.
503B outsourcing facility enforcement deadline (semaglutide)
FDA enforcement discretion ended for 503B outsourcing facilities on May 22, 2025. This effectively shut down the large-scale telehealth-compounded semaglutide market that had grown during the 2022-2024 shortage.
Source: FDA Compounding Policy Statement, Feb 2025. Verified 2026-04-27.
Date of FDA warning letters to Hims and Hers Health regarding compounded GLP-1 marketing
FDA issued warning letters to Hims and Hers on September 9, 2025, citing violations of FD&C Act § 502(a) (false or misleading labeling) and § 502(bb) regarding promotion of compounded semaglutide as equivalent to FDA-approved Wegovy/Ozempic. Specific phrases cited included “Same active ingredient as Ozempic and Wegovy” and “Clinically proven ingredients.”
Source: FDA Warning Letters Database; September 2025 actions. Verified 2026-04-27.
Date FDA approved Wegovy’s cardiovascular-risk-reduction indication
FDA approved an expanded label for Wegovy on March 8, 2024 to reduce risk of major adverse cardiovascular events in adults with established cardiovascular disease and BMI ≥27, based on the SELECT trial data. First obesity drug with a CV outcomes indication.
Source: FDA Press Release, March 8 2024. Verified 2026-04-27.
Date FDA approved Zepbound’s obstructive sleep apnea (OSA) indication
FDA approved Zepbound on December 20, 2024 for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. First medication approved for OSA in this population.
Source: FDA Press Release, December 20 2024. Verified 2026-04-27.
